WallStreetZenWallStreetZen

NASDAQ: VKTX
Viking Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VKTX

Based on 6 analysts offering 12 month price targets for Viking Therapeutics Inc

Min Forecast
$65.00+91.29%
Avg Forecast
$99.17+191.84%
Max Forecast
$125.00+267.86%

Should I buy or sell VKTX stock?

Based on 6 analysts offering ratings for Viking Therapeutics Inc.

Strong Buy
Strong Buy
5 analysts 83.33%
Buy
1 analysts 16.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although VKTX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates VKTX as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -12.86% per year. Learn More

Be the first to know when Wall Street analysts revise their VKTX stock forecasts and price targets.

VKTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-11
lockedlocked$00.00+00.00%2026-07-30Find Out Why
lockedlocked$00.00+00.00%2026-05-28
lockedlocked$00.00+00.00%2026-05-01
lockedlocked$00.00+00.00%2026-04-30
HC Wainwright & Co.
Top 6%
95
BuyReiterates$102.00+200.18%2026-03-23

1 of 1

Forecast return on equity

Is VKTX forecast to generate an efficient return?

Company
-43%
Industry
16.48%
Market
167.41%
VKTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VKTX forecast to generate an efficient return on assets?

Company
-33.64%
Industry
23.52%
VKTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VKTX earnings per share forecast

What is VKTX's earnings per share in the next 3 years based on estimates from 22 analysts?

Avg 1 year Forecast
-$4.54
Avg 2 year Forecast
-$4.50
Avg 3 year Forecast
-$3.86

VKTX revenue forecast

What is VKTX's revenue in the next 3 years based on estimates from 22 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$161.0M

VKTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VKTX$33.98$99.17+191.84%Strong Buy
IOVA$8.70$10.50+20.69%Strong Buy
TLX$11.74$21.33+81.71%Strong Buy
ADPT$24.57$24.42-0.62%Strong Buy
IDYA$39.97$49.50+23.84%Strong Buy
View Top Biotech Stocks

Viking Therapeutics Stock Forecast FAQ

Is Viking Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: VKTX) stock is to Strong Buy VKTX stock.

Out of 6 analysts, 5 (83.33%) are recommending VKTX as a Strong Buy, 1 (16.67%) are recommending VKTX as a Buy, 0 (0%) are recommending VKTX as a Hold, 0 (0%) are recommending VKTX as a Sell, and 0 (0%) are recommending VKTX as a Strong Sell.

If you're new to stock investing, here's how to buy Viking Therapeutics stock.

What is VKTX's earnings growth forecast for 2026-2028?

(NASDAQ: VKTX) Viking Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.25%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.98%.

Viking Therapeutics's earnings in 2026 is -$534,796,000.On average, 22 Wall Street analysts forecast VKTX's earnings for 2026 to be -$529,685,991, with the lowest VKTX earnings forecast at -$617,327,343, and the highest VKTX earnings forecast at -$134,734,142. On average, 22 Wall Street analysts forecast VKTX's earnings for 2027 to be -$524,868,225, with the lowest VKTX earnings forecast at -$728,217,625, and the highest VKTX earnings forecast at -$273,142,852.

In 2028, VKTX is forecast to generate -$449,965,374 in earnings, with the lowest earnings forecast at -$707,640,046 and the highest earnings forecast at -$68,591,927.

What is VKTX's revenue growth forecast for 2026-2028?

(NASDAQ: VKTX) Viking Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.33%.

Viking Therapeutics's revenue in 2026 is $0.On average, 22 Wall Street analysts forecast VKTX's revenue for 2026 to be $0, with the lowest VKTX revenue forecast at $0, and the highest VKTX revenue forecast at $0. On average, 22 Wall Street analysts forecast VKTX's revenue for 2027 to be $0, with the lowest VKTX revenue forecast at $0, and the highest VKTX revenue forecast at $0.

In 2028, VKTX is forecast to generate $18,782,289,386 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $82,578,614,102.

What is VKTX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: VKTX) forecast ROA is -33.64%, which is lower than the forecast US Biotechnology industry average of 23.52%.

What is VKTX's Price Target?

According to 6 Wall Street analysts that have issued a 1 year VKTX price target, the average VKTX price target is $99.17, with the highest VKTX stock price forecast at $125.00 and the lowest VKTX stock price forecast at $65.00.

On average, Wall Street analysts predict that Viking Therapeutics's share price could reach $99.17 by Aug 11, 2027. The average Viking Therapeutics stock price prediction forecasts a potential upside of 191.84% from the current VKTX share price of $33.98.

What is VKTX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: VKTX) Viking Therapeutics's current Earnings Per Share (EPS) is -$4.67. On average, analysts forecast that VKTX's EPS will be -$4.54 for 2026, with the lowest EPS forecast at -$5.29, and the highest EPS forecast at -$1.16. On average, analysts forecast that VKTX's EPS will be -$4.50 for 2027, with the lowest EPS forecast at -$6.24, and the highest EPS forecast at -$2.34. In 2028, VKTX's EPS is forecast to hit -$3.86 (min: -$6.07, max: -$0.59).

What is VKTX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: VKTX) forecast ROE is -43%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.